机构:[1]Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China[2]Department of Nephrology,Shenzhen Key Laboratory of Kidney Diseases, and Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People’s Hospital, the First Affiliated Hospital, Southern Universityof Science and Technology, Shenzhen 518020, China深圳市康宁医院深圳市人民医院深圳医学信息中心[3]National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University ofChinese Medicine, Nanchang 330004, China[4]China Academy of Chinese Medical Sciences, Beijing 100700, China[5]Department of Biological Sciences, National University ofSingapore, Singapore 117543, Singapore[6]Advanced Drug Delivery and Regenerative Biomaterials Laboratory, and Cardiovascular Pharmacology Division of CardiovascularInstitute, School of Medicine, Stanford University, Stanford, CA 94304, USA[7]Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, SouthernMedical University, Guangzhou 510515, China
We gratefully acknowledge financial support from the Establishment of Sino-Austria
“Belt and Road” Joint Laboratory on Traditional Chinese Medicine for Severe Infectious
Diseases and Joint Research (2020YFE0205100); the National Key Research and
Development Program of China (2020YFA0908000 and 2022YFC2303600); the
Innovation Team and Talents Cultivation Program of National Administration of
Traditional Chinese Medicine (ZYYCXTD-C-202002); the National Natural Science
Foundation of China (82141001, 82274182, 82074098 and 82173914); the CACMS
Innovation Fund (CI2021A05101 and CI2021A05104); the Scientific and Technological
Innovation Project of China Academy of Chinese Medical Sciences (CI2021B014); the
Science and Technology Foundation of Shenzhen (JCYJ20210324115800001); the
Fundamental Research Funds for the Central Public Welfare Research Institutes (ZZ14-
YQ-050, ZZ14-YQ-051, ZZ14-YQ-052, ZZ14-FL-002, ZZ14-ND-010 and ZZ15-ND-10); the
Shenzhen Governmental Sustainable Development Fund (KCXFZ20201221173612034);
the Shenzhen Key Laboratory of Kidney Diseases (ZDSYS201504301616234); the
Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties (SZGSP001).
第一作者机构:[1]Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China[2]Department of Nephrology,Shenzhen Key Laboratory of Kidney Diseases, and Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People’s Hospital, the First Affiliated Hospital, Southern Universityof Science and Technology, Shenzhen 518020, China
共同第一作者:
通讯作者:
通讯机构:[1]Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China[2]Department of Nephrology,Shenzhen Key Laboratory of Kidney Diseases, and Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People’s Hospital, the First Affiliated Hospital, Southern Universityof Science and Technology, Shenzhen 518020, China[3]National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University ofChinese Medicine, Nanchang 330004, China
推荐引用方式(GB/T 7714):
Xue-ling He,Jia-yun Chen,Yu-lin Feng,et al.Single-cell RNA sequencing deciphers the mechanism of sepsis-induced liver injury and the therapeutic effects of artesunate[J].ACTA PHARMACOLOGICA SINICA.2023,doi:10.1038/s41401-023-01065-y.
APA:
Xue-ling He,Jia-yun Chen,Yu-lin Feng,Ping Song,Yin Kwan Wong...&Ji-gang Wang.(2023).Single-cell RNA sequencing deciphers the mechanism of sepsis-induced liver injury and the therapeutic effects of artesunate.ACTA PHARMACOLOGICA SINICA,,
MLA:
Xue-ling He,et al."Single-cell RNA sequencing deciphers the mechanism of sepsis-induced liver injury and the therapeutic effects of artesunate".ACTA PHARMACOLOGICA SINICA .(2023)